Use of Fullerenes to Oxidize Reduced Redox Proteins

• US 20080020977A1
• Filed: 11/20/2006
• Published: 01/24/2008
• Est. Priority Date: 11/21/2005
• Status: Abandoned Application

• Current Assignee: Luna Innovations, Inc.
• Original Assignee: Luna Innovations, Inc.
• Inventors: Lebovitz, Russ
• Application Number:
  US11/561,520
• Publication Number:
  US 20080020977A1
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 1/006 of peptides containing derivatised side chain amino acids
• CPC Class Codes: C07K 14/80 Cytochromes

Abstract

Disclosed herein is a method of oxidizing a reduced redox protein by contacting an aqueous solution containing the reduced redox protein with a water-soluble substituted fullerene under conditions in which the water-soluble substituted fullerene can oxidize the reduced redox protein. The redox protein can be cytochrome c.

Claims

1. A method of oxidizing a reduced redox protein, comprising:

contacting an aqueous solution containing the reduced redox protein with a water-soluble substituted fullerene under conditions in which the water-soluble substituted fullerene can oxidize the reduced redox protein.

2. The method of claim 1, wherein the redox protein is a metalloprotein.

3. The method of claim 2, wherein the metalloprotein is a heme protein.

4. The method of claim 3, wherein the heme protein is a cytochrome.

5. The method of claim 4, wherein the cytochrome is cytochrome c.

6. The method of claim 1, wherein the redox protein is a flavoprotein.

7. The method of claim 1, wherein the water-soluble substituted fullerene is a dendrofullerene.

8. The method of claim 7, wherein the dendrofullerene is selected from the group consisting of DF-1, DF-1 Mini, PW71, PW75, PW79, PW80, PW85, PW87, PW88, PW104, PW114, and PW130.

9. The method of claim 1, wherein the water-soluble substituted fullerene is selected from the group consisting of C3 and esters thereof.

10. The method of claim 9, wherein the ester of C3 is selected from the group consisting of FB01, FB02, FB03, and FB10.

11. The method of claim 1, wherein the contacting step is performed in vivo.